Your browser is no longer supported. Please, upgrade your browser.
Settings
QURE uniQure N.V. daily Stock Chart
QURE [NASD]
uniQure N.V.
Index- P/E- EPS (ttm)-2.73 Insider Own1.10% Shs Outstand43.91M Perf Week16.60%
Market Cap2.87B Forward P/E- EPS next Y-3.21 Insider Trans-12.85% Shs Float38.20M Perf Month31.87%
Income-104.70M PEG- EPS next Q-0.75 Inst Own88.30% Short Float11.51% Perf Quarter37.18%
Sales6.30M P/S455.69 EPS this Y22.10% Inst Trans15.20% Short Ratio7.39 Perf Half Y-9.19%
Book/sh8.60 P/B7.60 EPS next Y-11.80% ROA-33.00% Target Price82.13 Perf Year114.36%
Cash/sh9.18 P/C7.12 EPS next 5Y- ROE-51.10% 52W Range24.07 - 82.49 Perf YTD126.86%
Dividend- P/FCF- EPS past 5Y1.20% ROI-41.10% 52W High-21.71% Beta0.79
Dividend %- Quick Ratio14.30 Sales past 5Y30.80% Gross Margin- 52W Low168.30% ATR2.96
Employees212 Current Ratio14.30 Sales Q/Q-67.70% Oper. Margin- RSI (14)74.62 Volatility4.88% 4.34%
OptionableYes Debt/Eq0.00 EPS Q/Q2.10% Profit Margin- Rel Volume1.24 Prev Close65.38
ShortableYes LT Debt/Eq0.10 EarningsNov 05 BMO Payout- Avg Volume594.70K Price64.58
Recom1.60 SMA2017.91% SMA5033.40% SMA20011.65% Volume737,085 Change-1.22%
Dec-03-19Initiated Goldman Buy
Dec-03-19Initiated Cowen Outperform
Nov-05-19Initiated Credit Suisse Outperform
Oct-11-19Initiated Stifel Buy
Sep-25-19Initiated Bernstein Outperform $73
Sep-12-19Initiated Mizuho Buy
Jul-30-19Downgrade Guggenheim Buy → Neutral
Jul-08-19Reiterated Cantor Fitzgerald Overweight $81 → $94
Apr-12-19Initiated Piper Jaffray Overweight $80
Mar-29-19Initiated Robert W. Baird Outperform $85
Mar-04-19Reiterated Chardan Capital Markets Buy $70 → $100
Feb-25-19Reiterated Cantor Fitzgerald Overweight $68 → $81
Feb-11-19Reiterated H.C. Wainwright Buy $60 → $73
Dec-31-18Resumed B. Riley FBR Buy $72
Nov-26-18Reiterated H.C. Wainwright Buy $48 → $60
Jul-27-18Initiated Cantor Fitzgerald Overweight $58
Jun-28-18Initiated B. Riley FBR, Inc. Buy $50
May-16-18Initiated Wells Fargo Outperform $47
May-07-18Reiterated Leerink Partners Outperform $26 → $63
Jan-04-18Initiated Janney Buy $25
Dec-05-19 09:37AM  4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal Zacks
03:49AM  Gene Therapy the Next Best Thing: Here's Why (Revised) Zacks
Dec-04-19 09:42AM  Gene Therapy the Next Best Thing: Here's Why Zacks
Dec-03-19 11:53AM  The Gene Therapy Names Moving On The Audentes Buyout Deal Benzinga +16.68%
Dec-02-19 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences in December GlobeNewswire
Nov-30-19 07:02PM  Hedge Funds Have Never Been This Bullish On Uniqure NV (QURE) Insider Monkey
Nov-22-19 10:16AM  Investors Hope for More From Takeda Than a Healthy Dividend GuruFocus.com
Nov-07-19 09:45AM  uniQure N.V. (QURE) Shares March Higher, Can It Continue? Zacks
Nov-06-19 09:16AM  uniQure Announces Clinical Data Presentations at the 61st American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Nov-05-19 07:00AM  uniQure Announces the Allowance of New Patent Providing Further Protection of the Padua and Padua-Related Variants of Factor IX in Gene Therapy GlobeNewswire
Nov-01-19 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences in November GlobeNewswire
Oct-31-19 07:00AM  uniQure Announces Publication of Positive Interim Data from Phase IIb Clinical Trial of Etranacogene Dezaparvovec GlobeNewswire
Oct-30-19 11:46AM  Are Insiders Selling uniQure N.V. (NASDAQ:QURE) Stock? Simply Wall St.
10:38AM  uniQure N.V. (QURE) Shares March Higher, Can It Continue? Zacks
Oct-29-19 12:37PM  Hedge Funds Have Never Been This Bullish On Uniqure NV (QURE) Insider Monkey
Oct-28-19 08:15AM  UniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates Zacks
07:00AM  uniQure Announces Third Quarter 2019 Results and Highlights Recent Company Progress GlobeNewswire
Oct-25-19 09:15AM  S&P, NASDAQ Up Again in Mixed Session Zacks +7.41%
Oct-02-19 09:33AM  Why this UC Berkeley gene therapy spinout is targeting a $100 million IPO American City Business Journals
Oct-01-19 01:43PM  Biotech Roundtable: How to Invest in Medicines Future Barrons.com -5.67%
Sep-30-19 11:10AM  Is uniQure N.V.'s (NASDAQ:QURE) CEO Pay Justified? Simply Wall St.
Sep-27-19 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences in October GlobeNewswire
Sep-26-19 10:34AM  Hedge Fund P.A.W. Capital Partners Top Stock Picks Insider Monkey -6.36%
Sep-05-19 08:39PM  uniQure Announces Pricing of its Public Offering GlobeNewswire -14.86%
08:12AM  The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug Benzinga
Sep-04-19 04:02PM  uniQure Announces Proposed Public Offering GlobeNewswire
Sep-03-19 07:00AM  uniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia B GlobeNewswire
Aug-30-19 08:32AM  uniQure (NASDAQ:QURE) Has Debt But No Earnings; Should You Worry? Simply Wall St.
07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences in September GlobeNewswire
Aug-20-19 07:00AM  uniQure Announces Leadership Promotions and Executive Transition GlobeNewswire
Aug-16-19 06:20AM  Gene therapies to test FDA's approach to regulating drugs after launch, experts say American City Business Journals
Jul-31-19 06:28AM  Introducing uniQure (NASDAQ:QURE), The Stock That Soared 653% In The Last Three Years Simply Wall St.
Jul-29-19 08:35AM  UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates Zacks -5.38%
07:18AM  uniQure Announces Second Quarter 2019 Results and Highlights Recent Company Progress GlobeNewswire
Jul-26-19 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
Jul-19-19 12:15PM  Uniqure Nv (QURE) CEO, CFO, Managing Director Matthew C Kapusta Sold $571,600 of Shares GuruFocus.com
Jul-11-19 05:33AM  Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study (Revised) Zacks
Jul-09-19 11:07AM  Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study Zacks
Jul-08-19 08:19AM  What Drove uniQure 171% Higher in the First Half of 2019 Motley Fool
Jul-06-19 07:00AM  uniQure Announces 36 Weeks of Follow-Up Data from Phase IIb Study of AMT-061 and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B GlobeNewswire
Jul-02-19 06:02AM  How Much Of uniQure N.V. (NASDAQ:QURE) Do Institutions Own? Simply Wall St.
Jun-29-19 08:25AM  The Week Ahead In Biotech: Pending Clinical Readouts In Focus Benzinga
Jun-22-19 09:33PM  Hedge Funds Have Never Been This Bullish On Uniqure NV (QURE) Insider Monkey
Jun-21-19 07:00AM  uniQure Announces Presentations at the Upcoming 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH) GlobeNewswire
Jun-20-19 09:41AM  The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure Zacks
Jun-19-19 11:20AM  Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal Zacks
Jun-18-19 09:15AM  Fed Week Begins in the Green Zacks
Jun-17-19 04:21PM  Why This Gene Therapy Stock Looks Like A Sure Takeover Bet: Analyst Investor's Business Daily +11.84%
09:41AM  Gene-Therapy Firm UniQure Explores Options Including Sale Bloomberg
09:33AM  UniQure Jumps on Report It's Exploring a Possible Sale TheStreet.com
Jun-11-19 08:47AM  Is the Options Market Predicting a Spike in uniQure (QURE) Stock? Zacks -12.02%
Jun-05-19 11:53AM  AMD and 3 more momentum stocks to watch MarketWatch
07:08AM  An Intrinsic Calculation For uniQure N.V. (NASDAQ:QURE) Suggests It's 29% Undervalued Simply Wall St.
Jun-04-19 09:01AM  uniQure (QURE) Jumps: Stock Rises 8.9% Zacks +9.44%
May-31-19 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
May-30-19 02:36PM  3 Top Gene Therapy Stocks That Could Soar InvestorPlace
May-22-19 07:00AM  uniQure Strengthens Intellectual Property Portfolio with Granted Patent Claims Covering AMT-130 for Huntingtons Disease GlobeNewswire
May-10-19 04:16PM  This Gene Therapy Stock Is Nearing A Breakout On Its Hemophilia B Study Investor's Business Daily +6.67%
02:44PM  uniQure N.V. (NASDAQ:QURE) Insiders Have Been Selling Simply Wall St.
08:00AM  uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B GlobeNewswire
May-07-19 07:00AM  uniQure Announces Featured Presentations of New Data on Spinocerebellar Ataxia Type 3 at the 2019 American Academy of Neurology Annual Meeting GlobeNewswire
May-02-19 04:26PM  Did Hedge Funds Drop The Ball On Uniqure NV (QURE) ? Insider Monkey
07:00AM  uniQure Announces New Preclinical Data in Hemophilia A and Fabry Disease in Oral Presentations at the 22nd ASGCT Annual Meeting GlobeNewswire
May-01-19 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
Apr-29-19 07:07AM  UniQure: 1Q Earnings Snapshot Associated Press
07:00AM  uniQure Announces First Quarter 2019 Results and Highlights Recent Company Progress GlobeNewswire
Apr-15-19 12:15PM  uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) GlobeNewswire
08:43AM  Want an insiders way to play IPOs? This fund has had outsize success with its strategy MarketWatch
Apr-08-19 09:45AM  4 Gene Therapy Players Likely to Become Buyout Targets in 2019 Zacks
07:00AM  uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntingtons Disease GlobeNewswire
Apr-04-19 02:36PM  uniQure N.V. (NASDAQ:QURE): Financial Strength Analysis Simply Wall St. +5.86%
Mar-29-19 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
Mar-10-19 10:36AM  10 Stocks For The Gene Therapy Revolution Investopedia
Mar-01-19 09:29PM  Why Big Pharma Is Diving Into Gene Therapy Barrons.com +6.15%
07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
Feb-28-19 07:00AM  uniQure Announces 2018 Financial Results and Highlights Recent Company Progress GlobeNewswire
Feb-27-19 09:53AM  The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure Zacks
07:00AM  uniQure Presents New Preclinical Data on AMT-130 at the CHDIs 14th Annual Huntingtons Disease Therapeutics Conference GlobeNewswire
Feb-26-19 11:15AM  Biotech ETFs Jump on Roche-Spark Deal Zacks
09:15AM  Deal on the Way Now that Deadline is Delayed? Zacks
08:54AM  5 Gene Therapy Stocks to Enrich Your Portfolio Zacks
07:19AM  2 More Gene Therapy Stocks on Big Pharma's Buyout Radar Motley Fool
Feb-25-19 03:12PM  Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal Benzinga +34.30%
Feb-22-19 07:45AM  Investor Expectations to Drive Momentum within Graphic Packaging Holding, Vulcan Materials, Omeros, Koppers, uniQure N.V, and WAVE Life Sciences Discovering Underlying Factors of Influence GlobeNewswire
Feb-15-19 07:24AM  uniQure Announces Publications on AAV Gene Therapy Approach to Treating Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) in the Journal Molecular Therapy Nucleic Acids GlobeNewswire
Feb-13-19 10:29AM  How Does Investing In uniQure N.V. (NASDAQ:QURE) Impact The Volatility Of Your Portfolio? Simply Wall St. -5.88%
Feb-08-19 07:26AM  UniQure gene therapy shows rise in blood-clotting protein in trial Reuters +9.98%
07:00AM  uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B GlobeNewswire
Feb-04-19 07:00AM  uniQure Announces First Patient Treated in HOPE-B Pivotal Trial of AMT-061 in Patients with Hemophilia B GlobeNewswire
Jan-30-19 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
Jan-22-19 07:00AM  uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-130 in Huntingtons Disease GlobeNewswire
Dec-18-18 02:13AM  Uniqure NV (QURE): Hedge Fund Sentiment Unchanged Insider Monkey
Dec-12-18 10:14AM  Do Institutions Own uniQure N.V. (NASDAQ:QURE) Shares? Simply Wall St.
Dec-04-18 09:12AM  FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101 Zacks
Dec-03-18 07:00AM  uniQure Announces Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 and Confirms Dose for AMT-061 Pivotal Study in Hemophilia B GlobeNewswire
Nov-30-18 08:00AM  Analysis: Positioning to Benefit within Vivint Solar, uniQure N.V, Internap, Intuit, WideOpenWest, and Deere Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-29-18 01:39PM  Bayer To Cut 12,000 Jobs Amid Strategic Overhaul To Focus On Pharma Investor's Business Daily
Nov-23-18 06:57AM  Novartis Gets Approval for Gene Therapy Luxturna in Europe Zacks
Nov-19-18 12:15PM  uniQure Highlights Pipeline Expansion and Advancements in Technology at Research & Development Day GlobeNewswire -9.11%
Nov-16-18 12:45PM  Uniqure CEO discusses company's positive data in hemophil... CNBC Videos
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126 for the treatment of heart failure. In addition, the company engages in developing AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment hemophilia A; AMT-190, a differentiated gene therapy for the treatment of Fabry disease; and AMT-150, a gene therapy for SCA3, a central nervous system disorder. The company has collaboration and license agreements with Bristol Myers-Squibb; 4D Molecular Therapeutics, LLC; and Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kapusta Matthew CCEO, CFO, Managing DirectorNov 20Sale53.748,000429,951367,652Nov 22 10:12 AM
Kuta Alexander Edward IIIExecutive VP, OperationsNov 15Option Exercise5.314,00021,24045,578Nov 19 08:51 AM
Kuta Alexander Edward IIIExecutive VP, OperationsNov 15Sale52.084,000208,31041,578Nov 19 08:51 AM
Kapusta Matthew CCEO, CFO, Managing DirectorOct 23Sale43.228,000345,781375,652Oct 25 08:38 AM
Kuta Alexander Edward IIIExecutive VP, OperationsOct 15Option Exercise5.314,00021,24045,578Oct 17 01:21 PM
Kuta Alexander Edward IIIExecutive VP, OperationsOct 15Sale42.354,000169,40041,578Oct 17 01:21 PM
Gut RobertChief Medical OfficerSep 19Sale47.164,769224,90635,378Sep 20 02:00 PM
Kapusta Matthew CCEO, CFO, Managing DirectorSep 18Sale47.318,000378,486383,652Sep 20 01:49 PM
Kuta Alexander Edward IIIExecutive VP, OperationsSep 16Option Exercise5.314,00021,24030,578Sep 18 01:25 PM
Kuta Alexander Edward IIIExecutive VP, OperationsSep 16Sale47.264,000189,04026,578Sep 18 01:25 PM
Kapusta Matthew CCEO, CFO, Managing DirectorAug 21Sale56.488,000451,840391,230Aug 23 10:43 AM
Astley-Sparke PhilipDirectorAug 01Sale60.126,460388,3446,812Aug 05 12:21 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJul 17Sale71.458,000571,616399,230Jul 19 10:37 AM
Kapusta Matthew CCEO, CFO, Managing DirectorJun 19Sale77.458,000619,626407,230Jun 20 11:03 AM
Astley-Sparke PhilipDirectorJun 03Sale63.636,000381,77913,272Jun 04 02:07 PM
Kapusta Matthew CCEO, CFO, Managing DirectorMay 15Sale58.388,000467,017415,230May 17 03:48 PM
KLEMT CHRISTIANChief Accounting OfficerApr 16Sale57.181,54688,40054,539Apr 17 11:09 AM
Astley-Sparke PhilipDirectorApr 01Sale59.846,000359,04019,272Apr 03 12:22 PM
Kapusta Matthew CCEO, CFO, Managing DirectorMar 14Sale63.0919,6881,242,081423,230Mar 15 03:15 PM
Kapusta Matthew CCEO, CFO, Managing DirectorMar 13Sale64.3247,6883,067,216442,918Mar 15 03:15 PM
Kuta Alexander Edward IIISVP, Regulatory AffairsFeb 15Option Exercise5.3120,000106,20046,578Feb 20 02:18 PM
Kuta Alexander Edward IIISVP, Regulatory AffairsFeb 15Sale35.828,000286,56038,578Feb 20 02:18 PM
Kaye JackDirectorJan 28Sale31.311,21037,88514,934Jan 31 05:19 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 28Sale31.4219,085599,651490,028Jan 30 07:15 PM
Balachandran MadhavanDirectorJan 28Sale31.311,21037,8856,812Jan 30 05:32 PM
Soteropoulos PaulaDirectorJan 28Sale31.321,21037,89719,934Jan 30 05:28 PM
SCHAFFER DAVIDDirectorJan 28Sale31.311,21037,88545,721Jan 30 05:24 PM
Astley-Sparke PhilipDirectorJan 28Sale31.321,21037,89725,272Jan 30 05:20 PM
van Deventer SanderChief Scientific OfficerJan 28Sale31.311,35842,51940,313Jan 30 05:01 PM
KLEMT CHRISTIANChief Accounting OfficerJan 28Sale31.291,47946,27856,085Jan 30 04:57 PM
Kuta Alexander Edward IIISVP, Regulatory AffairsJan 28Sale31.291,05232,91726,578Jan 30 04:55 PM
McMillan Scott T.Chief Operating OfficerJan 28Sale31.2359118,45720,432Jan 30 04:52 PM
Springhorn Jeremy P.DirectorJan 28Sale31.321,21037,8976,812Jan 30 04:49 PM
SCHAFFER DAVIDDirectorJan 17Sale30.717,500230,32543,701Jan 29 08:32 PM
KLEMT CHRISTIANChief Accounting OfficerJan 03Sale27.915,739160,17540,000Jan 07 11:21 AM